What is PE-22-28?
PE-22-28 is a short spadin-derived peptide investigated as a TREK-1 channel inhibitor in cell experiments and rodent behavioural models. It is not a hair-growth or GPR44/CRTH2 peptide. No validated human dose, route, preparation or clinical use has been established.
Research classification: Research summary · not a validated human regimen. The PE-22-28 10 mg vial label reports nominal content; it does not state a suitable amount for human use.
Mechanism and research questions
Spadin-derived analog studied for inhibition of the TREK-1 potassium channel and antidepressant-like effects in rodent behavioural experiments; these findings do not establish clinical efficacy.
Mechanistic findings and early experiments do not by themselves establish clinical efficacy, an approved treatment cycle or equivalence between suppliers' formulations. Interpret claims in the context of the specific experimental model and references.
How to read a reported schedule
The primary spadin-analogue study evaluated TREK-1 inhibition in cells and antidepressant-like behaviour in mice. PE-22-28 is not a hair-growth or GPR44 peptide, and this experiment cannot establish a human route, amount, timing or treatment cycle.
For the existing schedule, its evidence caveats and the concentration calculator, see the PE-22-28 protocol and vial reference. Figures displayed there are research context, not a personalised prescription.
Vial identity and preparation
An exact-matching Peak Peptides Australia 10 mg vial is shown on the research reference page. The product is supplied for in-vitro research, not administration.
Reconstitution cannot be inferred from vial strength alone. Confirm the exact compound, lot, expected appearance, compatible sterile diluent, final volume, transfer method and discard/storage period from validated formulation documentation. BAC water and a 28-day period are not universal defaults. See the illustrated product-specific preparation guide and the abnormal-solution safety guide.
View Peak Peptides Australia's research-only listing and confirm its current labelled strength.
Sources, limits and next steps
No independently reviewed primary human protocol has been attached to this catalogue article. A cited bibliography should be obtained before interpreting any reported schedule.
For clinical decisions, consult a qualified professional and the product information for an approved formulation. Research-only supplier material must not be injected or used to treat a condition. Explore the A–Z research directory to compare evidence categories.